Chronic loss of inhibitor-1 diminishes cardiac RyR2 phosphorylation despite exaggerated CaMKII activity

被引:9
作者
Neef, Stefan [1 ]
Heijman, Jordi [2 ]
Otte, Kristian [3 ]
Dewenter, Matthias [3 ,4 ]
Saadatmand, Ali R. [3 ,4 ]
Meyer-Roxlau, Stefanie [3 ]
Antos, Christopher L. [3 ]
Backs, Johannes [4 ]
Dobrev, Dobromir [5 ]
Wagner, Michael [3 ]
Maier, Lars S. [1 ]
El-Armouche, Ali [3 ]
机构
[1] Univ Hosp Regensburg, Dept Internal Med 2, Regensburg, Germany
[2] Maastricht Univ, CARIM Sch Cardiovasc Dis, Dept Cardiol, Maastricht, Netherlands
[3] Tech Univ Dresden, Carl Gustav Carus Fac Med, Dept Pharmacol & Toxicol, Dresden, Germany
[4] Heidelberg Univ, Dept Cardiol, Heidelberg, Germany
[5] Univ Duisburg Essen, Inst Pharmacol, West German Heart & Vasc Ctr, Essen, Germany
关键词
Inhibitor-1; Ca2+/calmodulin-dependent protein kinase II; Protein phosphatase 1; Ryanodine receptor; PROTEIN PHOSPHATASE-1 INHIBITOR-1; MYOCARDIAL HYPERTROPHY; HEART-FAILURE; MYOCYTES;
D O I
10.1007/s00210-017-1376-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inhibitor-1 (I-1) modulates protein phosphatase 1 (PP1) activity and thereby counteracts the phosphorylation by kinases. I-1 is downregulated and deactivated in failing hearts, but whether its role is beneficial or detrimental remains controversial, and opposing therapeutic strategies have been proposed. Overactivity of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with hyperphosphorylation of ryanodine receptors (RyR2) at the CaMKII-site is recognized to be central for heart failure and arrhythmias. Using an I-1-deficient mouse line as well as transfected cell lines, we investigated the effects of acute and chronic modulation of I-1 on CaMKII activity and RyR2 phosphorylation. We demonstrate that I-1 acutely modulates CaMKII by regulating PP1 activity. However, while ablation of I-1 should thus limit CaMKII-activation, we unexpectedly found exaggerated CaMKII-activation under beta-adrenergic stress upon chronic loss of I-1 in knockout mice. We unraveled that this is due to chronic upregulation of the exchange protein activated by cAMP (EPAC) leading to augmented CaMKII activation, and using computational modeling validated that an increase in EPAC expression can indeed explain our experimental findings. Interestingly, at the level of RyR2, the increase in PP1 activity more than outweighed the increase in CaMKII activity, resulting in reduced RyR phosphorylation at Ser-2814. Exaggerated CaMKII activation due to counterregulatory mechanisms upon loss of I-1 is an important caveat with respect to suggested therapeutic I-1-inhibition, as CaMKII overactivity has been heavily implicated in several cardiac pathologies.
引用
收藏
页码:857 / 862
页数:6
相关论文
共 18 条
  • [1] Protein phosphatase-1 regulation in the induction of long-term potentiation: Heterogeneous molecular mechanisms
    Allen, PB
    Hvalby, O
    Jensen, V
    Errington, ML
    Ramsay, M
    Chaudhry, FA
    Bliss, TVP
    Storm-Mathisen, J
    Morris, RGM
    Andersen, P
    Greengard, P
    [J]. JOURNAL OF NEUROSCIENCE, 2000, 20 (10) : 3537 - 3543
  • [2] CaMKII in myocardial hypertrophy and heart failure
    Anderson, Mark E.
    Brown, Joan Heller
    Bers, Donald M.
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 51 (04) : 468 - 473
  • [3] CaM kinase II selectively signals to histone deacetylase 4 during cardiornyocyte hypertrophy
    Backs, Johannes
    Song, Kunhua
    Bezprozvannaya, Svetlana
    Chang, Shurong
    Olson, Eric N.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (07) : 1853 - 1864
  • [4] Type 1 phosphatase, a negative regulator of cardiac function
    Carr, AN
    Schmidt, AG
    Suzuki, Y
    del Monte, F
    Sato, Y
    Lanner, C
    Breeden, K
    Jing, SL
    Allen, PB
    Greengard, P
    Yatani, A
    Hoit, BD
    Grupp, IL
    Hajjar, RJ
    DePaoli-Roach, AA
    Kranias, EG
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (12) : 4124 - 4135
  • [5] Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts
    El-Armouche, A
    Pamminger, T
    Ditz, D
    Zolk, O
    Eschenhagen, T
    [J]. CARDIOVASCULAR RESEARCH, 2004, 61 (01) : 87 - 93
  • [6] Evidence for protein phosphatase inhibitor-1 playing an amplifier role in β-adrenergic signaling in cardiac myocytes
    El-Armouche, A
    Rau, T
    Zolk, O
    Ditz, D
    Pamminger, T
    Zimmermann, WH
    Jäckel, E
    Harding, SE
    Boknik, P
    Neumann, J
    Eschenhagen, T
    [J]. FASEB JOURNAL, 2003, 17 (01) : 437 - +
  • [7] Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy
    El-Armouche, Ali
    Wittkoepper, Katrin
    Degenhardt, Franziska
    Weinberger, Florian
    Didie, Michael
    Melnychenko, Ivan
    Grimm, Michael
    Peeck, Micha
    Zimmermann, Wolfram H.
    Unsoeld, Bernhard
    Hasenfuss, Gerd
    Dobrev, Dobromir
    Eschenhagen, Thomas
    [J]. CARDIOVASCULAR RESEARCH, 2008, 80 (03) : 396 - 406
  • [8] Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes
    El-Armouche, Ali
    Bednorz, Anna
    Pamminger, Torsten
    Ditz, Diana
    Didie, Michael
    Dobrev, Dobromir
    Eschenhagen, Thomas
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 346 (03) : 700 - 706
  • [9] Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging
    Florea, Stela
    Anjak, Ahmad
    Cai, Wen-Feng
    Qian, Jiang
    Vafiadaki, Elizabeth
    Figueria, Sarah
    Haghighi, Kobra
    Rubinstein, Jack
    Lorenz, John
    Kranias, Evangelia G.
    [J]. BASIC RESEARCH IN CARDIOLOGY, 2012, 107 (05)
  • [10] Local control of β-adrenergic stimulation: Effects on ventricular myocyte electrophysiology and Ca2+-transient
    Heijman, Jordi
    Volders, Paul G. A.
    Westra, Ronald L.
    Rudy, Yoram
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 50 (05) : 863 - 871